Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin™ for active targeting

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 58, Issue 3, 2004, Pages 483-490

  Nobs, Leila ^a   Buchegger, Franz ^b   Gurny, Robert ^a   Allémann, Eric ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Drug targeting; Nanoparticles; NeutrAvidin ; Poly(DL lactic acid); Sulfhydryl functions; Surface chemistry

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; AVIDIN; BIOTIN; CYANAMIDE; NANOPARTICLE; NEUTRAVIDIN; PHOSPHINE DERIVATIVE; POLYLACTIC ACID; PROTEIN; RHODAMINE; RHODAMINE RED; THIOL GROUP; TRIS(2 CARBOXYETHYL)PHOSPHINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOTINYLATION; CHEMICAL REACTION; CROSS LINKING; DRUG TARGETING; EVALUATION; PARTICLE SIZE; PROTEIN BINDING; PROTEIN CONTENT; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE;

AVIDIN; DRUG DELIVERY SYSTEMS; LACTIC ACID; NANOSTRUCTURES; POLYMERS;

EID: 4644296183     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2004.04.006     Document Type: Article

References (24)

1. Krause H.-J., Schwarz A., Rohdewald P. Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs. Int. J. Pharm. 27:1985;145-155
2. Allémann E., Gurny R., Doelker E. Drug-loaded nanoparticles- preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 39:1993;173-191
3. Bazile D., Prud'Homme C., Bassoullet M.-T., Marlard M., Spenlehauer G., Veillard M., Stealth M. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84:1995;493-498
4. Zambaux M.F., Bonneaux F., Gref R., Dellacherie E., Vigneron C. MPEO-PLA nanoparticles: effect of MPEO content on some of their surface properties. J. Biomed. Mater. Res. 44:1999;109-115
5. Verrecchia T., Spenlehauer G., Murry-Brelier A., Archimbaud Y., Veillard M. Non-stealth (poly(lactic acid/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J. Control. Release. 36:1995;49-61
6. Allémann E., Brasseur N., Benrezzak O., Rousseau J., Kudrevich S.V., Boyle R.W., Leroux J.C., Gurny R., Van Lier J.E. PEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumours. J. Pharm. Pharmacol. 47:1995;382-387
7. Kubiak C., Manil L., Couvreur P. Sorptive properties of antibodies onto cyanoacrylic nanoparticles. Int. J. Pharm. 41:1988;181-187
8. Illum L., Jones P.D., Baldwin R.W., Davis S.S. Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts. J. Pharmacol. Exp. Ther. 230:1984;733-736
9. Illum L., Jones P.D.E., Kreuter J., Baldwin R.W., Davis S.S. Adsorption of monoclonal antibodies to polyhexylcyanoacrylate nanoparticles and subsequent immunospecific binding to tumour cells in vitro. Int. J. Pharm. 17:1983;65-76
10. Couvreur P., Aubry J. Monoclonal antibodies for the targeting of drugs: application to nanoparticles. Topics Pham. Sci. 1983;305-316
11. Rolland A., Bourel D., Genetet B., Le Verge R. Monoclonal antibodies covalently coupled to polymethacrylic nanoparticles: in vitro specific targeting to human T lymphocytes. Int. J. Pharm. 39:1987;173-180
12. Akasaka Y., Ueda H., Takayama K., Machida Y., Nagai T. Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. Drug Des. Deliv. 3:1988;85-97
13. Jiang F.N., Jiang S., Liu D., Richter A., Levy J.G. Development of technology for linking photosensitizers to a model monoclonal antibody. J. Immunol. Methods. 134:1990;139-149
14. Magnani P., Paganelli G., Modorati G., Zito F., Songini C., Sudati F., Koch P., Maecke H.R., Brancato R., Siccardi A.G., Fazio F. Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J. Nucl. Med. 37:1996;967-971
15. Casalini P., Luison E., Ménard S., Colnaghi M.I., Paganelli G., Canevari S. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J. Nucl. Med. 38:1997;1378-1381
16. Nobs L., Buchegger F., Gurny R., Allémann E. Surface modification of poly(lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods. Int. J. Pharm. 250:2003;327-337
17. De Jaeghere F., Allémann E., Feijen J., Kissel T., Doelker E., Gurny R. Freeze-drying and lyopreservation of diblock and triblock poly(lactic acid)-poly(ethylene oxide) (PLA-PEO) copolymer nanoparticles. Pharm. Dev. Technol. 5:2000;473-483
18. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:1959;70-77
19. Kada G., Falk H., Gruber H.J. Accurate measurement of avidin and streptavidin in crude biofluid with a new, optimized biotin-fluorescein conjugate. Biochem. Biophys. Acta. 1427:1999;33-43
20. Hiller Y., Gershoni J.M., Bayer E.A., Wilchek M. Biotin binding to avidin. Biochem. J. 248:1987;167-171
21. Langer K., Coester C., Weber C., Von Briesen H., Kreuter J. Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. Eur. J. Pharm. Biopharm. 49:2000;303-307
22. Banga A.K. Lyophilization as a pharmaceutical process. in: Processing and Handling of Therapeutic peptides and proteins. 1995;Technomic Publishing Company, Lancaster. pp. 135-139
23. Gruber H.J., Kada G., Marek M., Kaiser K. Accurate titration of avidin and streptavidin with biotin-fluorophore conjugates in complex, colored biofluids. Biochim. Biophys. Acta. 1381:1998;203-212
24. Gonzalez M., Bagatolli L.A., Echabe I., Arrondo J.L., Argarana C.E., Cantor C.R., Fidelio G.D. Interaction of biotin with streptavidin. Thermostability and conformational changes upon binding. J. Biol. Chem. 272:1997;11288-11294